Evidence map›Paper›PMID 31915861›Full record

Trial reportPsychopharmacology2020

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.

E Appiah-Kusi, N Petros, R Wilson, M Colizzi, M G Bossong, L Valmaggia, V Mondelli, P McGuire, S Bhattacharyya

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 7 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 7 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The Autism-Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System.International journal of environmental research and public health · 2022
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Schizophrenia bulletin open · 2024
    Article
  18. The therapeutic potential of purified cannabidiol.Journal of cannabis research · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

E Appiah-KusiDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
N PetrosDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
R WilsonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
M ColizziDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
M G BossongDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
L ValmaggiaDepartment of Psychology, IoPPN, King's College London, London, PO Box 77, UK.
V MondelliNational Institute for Health Research, Biomedical Research Centre, London, UK.
P McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
S BhattacharyyaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, PO Box 63, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK. sagnik.2.bhattacharyya@kcl.ac.uk.ORCID http://orcid.org/0000-0002-8688-8025
King's College London · GBUniversity of Verona · IT

Funding

Department of Health EME/16/126/53Medical Research Council MR/J012149/1National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation TrustNational Institute for Health Research NIHR CS-11-001Nederlandse Organisatie voor Wetenschappelijk Onderzoek Veni FellowshipWellcome Trust
6 · The paper itself

Abstract

rationaleStress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects.

objectivesWe investigated whether CBD would normalise the neuroendocrine and anxiety responses to stress in clinical high risk for psychosis (CHR) patients.

methodsThirty-two CHR patients and 26 healthy controls (HC) took part in the Trier Social Stress Test (TSST) and their serum cortisol, anxiety and stress associated with public speaking were estimated. Half of the CHR participants were on 600 mg/day of CBD (CHR-CBD) and half were on placebo (CHR-P) for 1 week.

resultsOne-way analysis of variance (ANOVA) revealed a significant effect of group (HC, CHR-P, CHR-CBD (p = .005) on cortisol reactivity as well as a significant (p = .003) linear decrease. The change in cortisol associated with experimental stress exposure was greatest in HC controls and least in CHR-P patients, with CHR-CBD patients exhibiting an intermediate response. Planned contrasts revealed that the cortisol reactivity was significantly different in HC compared with CHR-P (p = .003), and in HC compared with CHR-CBD (p = .014), but was not different between CHR-P and CHR-CBD (p = .70). Across the participant groups (CHR-P, CHR-CBD and HC), changes in anxiety and experience of public speaking stress (all p's < .02) were greatest in the CHR-P and least in the HC, with CHR-CBD participants demonstrating an intermediate level of change.

conclusionsOur findings show that it is worthwhile to design further well powered studies which investigate whether CBD may be used to affect cortisol response in clinical high risk for psychosis patients and any effect this may have on symptoms.

Indexed as

Social BehaviorAdolescentAdultAnti-Anxiety AgentsAntipsychotic AgentsAnxietyCannabidiolDouble-Blind MethodFemaleHumansHydrocortisoneMalePsychotic DisordersRisk FactorsSpeechStress, PsychologicalAnti-Anxiety AgentsAntipsychotic AgentsCannabidiolHydrocortisoneCannabidiolPsychosisTrier Social Stress TestUltra-high risk

Identifiers

PMID31915861
PMCPMC7113209
OpenAlexW2999326643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.